Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05751447

Sarcoidosis and Immune Cells in Lung, Lymph Nodes and Blood

Studie Av Cellulära Uttryck I Lymfkörtlar, Lungsköljvätska Och Blod Vid Sarkoidos.

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
560 (estimated)
Sponsor
Region Stockholm · Other Government
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

Background: Sarcoidosis is an inflammatory disease, most commonly affecting the lungs and intrathoracic lymph nodes but can affect virtually any organ, sometimes manifesting as life threatening cardiac arrythmias. Some patients resolve spontaneously, whereas others get a chronic disease leading to for instance impaired lung function and cardiac failure. The most severe cases might need a transplantation. In the lungs, activated T cells are accumulated leading to release of cytokines, especially TNF-alpha is regarded as crucial for disease progression. Some segments of the T cell receptor and specific genes (HLA types) are connected to a resolving disease. More detailed knowledge about mechanisms why some experience a chronic disease course and others resolve spontaneously without treatment is to a large extent lacking. There is no cure, and despite treatment with immunosuppressants (often corticosteroids and cytotoxic agents), many patients experience a deteriorating disease. Aim: 1. Find biomarkers to be able to early predict which patients will develop a more severe/ chronic disease course and thereby enabeling early intervention before irreversible damage. 2. Predict which treatment is best for a specific patient, i.e. individualize treatment. 3. Find targets for new potential therapies. Methods: The majority of data is collected at investigations normally performed during diagnostic work-up for sarcoidosis. Most patients undergo a bronchoscopy with bronchoalveolar lavage (BAL) and some also lymph node punction through oesophagus with the help of ultrasound. The BAL fluid that remains after clinical analysis is used for research purpose. For patients undergoing lymph node punction, one extra punction is performed for research purpose. Extra blood samples are taken from all patients. The samples will mostly be used for studying T cells with immunohistochemistry, flow cytometry including activity markers, subtypes and receptors, but also cytokines and other cells (for instance B cells, NK and NKT cells). The patients are followed longitudinally, minimum 2 years. Some patients will undergo a second bronchoscopy 6-12 months after the first. Results from the immunological investigations will be correlated to disease course, genetics and result of treatment. Significance : By comparing the inflammation in several compartments (lung, lymph node , blood) at a molecular level with clinical disease course, genotype, and treatment response we hope to find biomarkers that can predict disease course and response to therapy. Thereby, we hope to be able to tailor therapy for each individual patient. By studying several compartments, the results may also help to improve understanding of how a systemic inflammation is distributed within the body, and thus also contribute to understanding of other inflammatory diseases.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTLymph node puncture, bronchoscopyIncluded patients will undergo an extra lympn node punction through oesophagus and/ or an extra bronchoscopy.

Timeline

Start date
2019-10-01
Primary completion
2034-05-01
Completion
2034-05-01
First posted
2023-03-02
Last updated
2024-10-04

Locations

1 site across 1 country: Sweden

Source: ClinicalTrials.gov record NCT05751447. Inclusion in this directory is not an endorsement.